A guiding philosophy shaping how the company operates, partners, and grows in the U.S. generics market
Parsippany, NJ – May 8, 2026 – YARAL Pharma Inc. (YARAL Pharma), the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today reinforced its commitment to Doing Things Differently – a guiding philosophy shaping the company’s initiatives in 2026 and informing how it defines success in the U.S. generics market. Throughout the year, YARAL Pharma will integrate the Doing Things Differently tagline across its corporate branding, marketing, and sales efforts.
Founded in 2022, YARAL Pharma entered the U.S. market with a deliberate strategy to challenge the traditional high-volume, commoditized generics model. Instead, the company has focused on “winning with the right marbles,” prioritizing differentiated, complex, and niche products that create sustainable value, through right pricing, continuity of supply and service levels. This philosophy serves as the foundation for YARAL Pharma’s Doing Things Differently approach.
“At YARAL, we are redefining what it means to be a generics company,” said Stephen Beckman, CEO, YARAL Pharma. “Doing Things Differently reflects our belief that patients, pharmacists, and healthcare partners deserve more consistency, more innovation, and more accountability. That commitment shows up in more ways than just access to affordable medicine and shows in the way we operate, partner, and grow—every day.”
Doing Things Differently serves as a unifying platform across YARAL Pharma’s communications and strategic initiatives reinforcing the company’s focus on:
- Raising the bar for quality and supply reliability within the generics space
- Investing in customer-first service and responsiveness
- Building strong, transparent relationships with pharmacists, wholesalers, and healthcare systems
- Driving meaningful innovation in how generics are delivered to the market
- Operating with agility and accountability as the company continues its rapid growth trajectory
To learn more about YARAL Pharma’s commitment to Doing Things Differently, visit:
www.yaralpharma.com.
About YARAL Pharma
YARAL Pharma Inc. (Parsippany, N.J.) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the U.S. market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaralpharma.com or contact info@yaralpharma.com or 866-218-9009.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,500 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.
Media Contact
Daina Basile
Kovak-Likly Communications
dbasile@klcpr.com
YPM-1519-EN-v1